AMINOALKYLTHIAZOLE DERIVATIVE
    61.
    发明公开
    AMINOALKYLTHIAZOLE DERIVATIVE 失效
    氨基烷基噻唑衍生物

    公开(公告)号:EP0641788A1

    公开(公告)日:1995-03-08

    申请号:EP92910766.2

    申请日:1992-05-29

    IPC分类号: C07D277/40

    CPC分类号: C07D277/40

    摘要: Object to provide an antipsychotic having a mechanism of action different from that of a dopamine autoreceptor agonist, that is, an antipsychotic having a specific affinity for a sigma receptor and not causing extrapyramidal disorder. Constitution: an aminoalkylthiazole derivative represented by general formula (I) and a salt thereof, wherein R¹ represents halogenated phenyl; R² and R³ may be the same or different from each other and each represents C₄ to C₁₀ alkyl; and n represents 2 or 3.

    摘要翻译: 目的是提供具有不同于多巴胺自身受体激动剂作用机制的抗精神病药物,即对σ受体具有特异性亲和力并且不引起锥体束外疾病的抗精神病药物。 组成:由通式(Ⅰ)表示的氨烷基噻唑衍生物及其盐,其中R 1代表卤代苯基; R 2和R 3可以相同或不同,各自代表C 4至C 10烷基; 并且n代表2或3。

    PROSTAGLANDIN E 1? ANALOGUE
    66.
    发明公开
    PROSTAGLANDIN E 1? ANALOGUE 失效
    前列腺素E 1? 类似物

    公开(公告)号:EP0591532A1

    公开(公告)日:1994-04-13

    申请号:EP92908341.8

    申请日:1992-04-21

    IPC分类号: C07C405/00

    CPC分类号: C07C405/00

    摘要: Object: to provide a novel prostaglandin E₁ which is excellent in drug efficacy and prolonged action while reduced in adverse reactions as compared with conventional ones. Constitution: a PGE₁ analogue represented by general formula (I) and its salt, wherein R¹ represents hydrogen, C₁ to C₆ alkyl or aryl; and R² represents C₃ to C₆ alkyl or C₃ to C₆ alkenyl.

    摘要翻译: 目的:提供一种新颖的前列腺素E 1,其与常规药物相比在药物疗效和延长作用方面优异,并且在不良反应中减少。 组成:由通式(Ⅰ)代表的PGE 1类似物及其盐,其中R 1代表氢,C 1至C 6烷基或芳基; R 2代表C 3至C 6烷基或C 3至C 6链烯基。

    STRESS SCATTERING METHOD IN TABLETING
    69.
    发明授权
    STRESS SCATTERING METHOD IN TABLETING 失效
    方法用于分发压力,将数位板动物。

    公开(公告)号:EP0401389B1

    公开(公告)日:1994-03-02

    申请号:EP90901016.7

    申请日:1989-12-28

    IPC分类号: A61K9/20

    CPC分类号: A61K9/2081 A61K9/2063

    摘要: This invention relates to a tableting composition containing minute gelatine balls and/or foams as stress scattering agents so as to minimize the disintegration of microcapsules or the transformation of medicine during tableting; and a stress scattering method in tableting. The use of the tableting composition according to the present invention enables tablets to be made without causing microencapsulated medicine powder, enzymes, germs or substances of a low melting point to be transformed or disintegrated.